QNCX · Current Report (Form 8-K) · Filed May 18, 2026

Quince Therapeutics Inc — 8-K exhibit

d109149dex105.htm

Quince Therapeutics Inc on Boardroom Alpha

EX-10.5

Exhibit 10.5

LOGO

May 17, 2026

Dirk Thye

RE: Retention Bonus

Dirk,

Quince feels it is in our best interest to retain you in order to ensure continuity of operations. We would like to offer you, based on the milestone below, a bonus totaling $700,000.00. The bonus will be paid if you remain employed by Parent through the date of stockholder approval of matters relating to Quince’s acquisition of OrphAI Therapeutics, Inc.

This payment is subject to all applicable deductions and withholdings and will be paid out on the first available payroll date after the milestone is met. This agreement does not change the at-will employment relationship.

In addition, by signing below you agree that Section 3(b)(iv) of that certain Executive Change in Control Agreement between you and Quince dated May 19, 2022 be and hereby is deleted in its entirety.

/s/ David Lamond

David Lamond

Chairman of the Board

Acknowledged and Agreed To:

/s/ Dirk Thye

Dirk Thye

611 Gateway Boulevard • Suite 273 • South San Francisco • California • 94080

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer